⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
NVO News
Novo-Nordisk A/S
Parker Waichman LLP Files Lawsuit on behalf of South Carolina Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic
prnewswire.com
NVO
Refills GLP-1 Weight Loss Claims Evaluated: The Most Affordable Personalized Semaglutide & Tirzepatide GLP1 Program with Online Doctor Support
globenewswire.com
LLY
NVO
Novo Nordisk's Ozempic® pill, the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes, soon to be available in the US
prnewswire.com
NVO
What the U.S. Pharmaceutical Industry Could Learn from How Africa Solves Patient Access
accessnewswire.com
PFE
SNY
NVO
WEBINAR INVITATION: Novo Resources Corp. Executive Co-Chairman to discuss the March Quarter Activities and Outlook
globenewswire.com
NVO
SQM
Novolog or Novomix or NovoRapid (Novo Nordisk) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F
globenewswire.com
NVO
Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM USA - English USA - English
prnewswire.com
NVO
Denecimig (Mim8) significantly reduced annualized bleeding rate in people with hemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM
prnewswire.com
NVO
Novo Nordisk A/S: Denecimig (Mim8) significantly reduced annualised bleeding rate in people with haemophilia A, regardless of inhibitor status, in phase 3 data published in NEJM
globenewswire.com
NVO
Novo Resources Provides Business Update
globenewswire.com
NVO
SQM
AGL